Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
NCT01165307 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 77
Last updated 2017-01-20
Summary
Excessive menstrual loss (menorrhagia) is a common condition that affects women of reproductive age, and can result in anemia, chronic fatigue and lost wages from work. The traditional first line management involves treatment with oral contraceptives or non-steroidal anti-inflammatory agents. Many women ultimately undergo hysterectomy, a major operative procedure associated with increased costs, loss of feeling of womanhood, debilitating complications and on rare occasions, death.
The newer global endometrial ablation (GEA) devices allow the destruction of the endometrial lining, without the removal of the uterus, in an ambulatory surgery setting. GEA offers a safe and effective alternative to hysterectomy with minimal risks and without unpleasant side-effects.
Presently, global endometrial ablation is offered as an alternative to hysterectomy, after medical intervention has failed. This study will determine the role of global endometrial ablation in the initial management of menorrhagia. Women seeking treatment for menorrhagia will be randomized to either the medical treatment arm or the global endometrial ablation arm.
This study will be the first to compare clinical efficacy and costs between oral contraceptive pills and global endometrial ablation in the initial management of menorrhagia and could potentially change the management of menorrhagia and impact millions of women who suffer from this condition.
Conditions
- Menorrhagia
Interventions
- DRUG
-
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills
Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
- DRUG
-
Naproxen sodium pills
As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
- DEVICE
-
NovaSure® Radiofrequency Endometrial Ablation
Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
Sponsors & Collaborators
-
Hologic, Inc.
collaborator INDUSTRY -
Abimbola Famuyide
lead OTHER
Principal Investigators
-
Abimbola O. Famuyide, MBBS · Mayo Clinic
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 55 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-08-31
- Primary Completion
- 2015-09-30
- Completion
- 2015-10-31
Countries
- United States
Study Locations
More Related Trials
-
The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.
NCT03509168 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Trial of Mifepristone for Fibroids
NCT00133705 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test
NCT01740687 ·Status: COMPLETED
-
Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy
NCT07286188 ·Status: RECRUITING ·Phase: PHASE4
-
Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy
NCT02716142 ·Status: COMPLETED ·Phase: PHASE4
-
A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy
NCT03210324 ·Status: TERMINATED ·Phase: PHASE4
-
Misoprostol for the Treatment of Postpartum Hemorrhage
NCT00116350 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding
NCT07169214 ·Status: RECRUITING ·Phase: PHASE1
-
Management of Abnormal Uterine Bleeding
NCT06369012 ·Status: COMPLETED ·Phase: NA
-
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
NCT03638856 ·Status: COMPLETED ·Phase: NA
-
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
NCT02853552 ·Status: UNKNOWN ·Phase: PHASE4
-
Misoprostol for Reduction of Blood Loss During Fibroid Surgery
NCT02209545 ·Status: TERMINATED ·Phase: PHASE4
-
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
NCT00147420 ·Status: COMPLETED ·Phase: NA
-
Long-term Use of Mifepristone in the Treatment of Adenomyosis
NCT05151016 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Misoprostol Dosing in BMI Greater Than 30
NCT05262738 ·Status: COMPLETED ·Phase: PHASE4
-
Sublingual Misoprostol in Decreasing Blood Loss Prior to Myomectomy
NCT02709564 ·Status: COMPLETED ·Phase: PHASE3
-
Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol
NCT01762319 ·Status: UNKNOWN ·Phase: NA
-
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
NCT06114758 ·Status: ACTIVE_NOT_RECRUITING
-
Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy
NCT02154932 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids
NCT00881140 ·Status: COMPLETED ·Phase: PHASE2
-
Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
NCT03064568 ·Status: COMPLETED ·Phase: PHASE4
-
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
NCT03584854 ·Status: COMPLETED ·Phase: PHASE4
-
the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation
NCT03483142 ·Status: UNKNOWN ·Phase: PHASE3
-
Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy
NCT03122782 ·Status: UNKNOWN ·Phase: PHASE3
-
Misoprostol For Nulliparous Women Before Hysteroscopy
NCT01156948 ·Status: UNKNOWN ·Phase: PHASE3